Form 4: Relay Therapeutics Officer Sells Shares to Cover Tax Obligations

Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold 400 shares of common stock on December 27, 2024, to cover income tax withholding obligations upon the vesting of restricted stock units.

Summary

• On December 27, 2024, Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold 400 shares of common stock at a price of $4.38 per share.
• The sale was executed to cover income tax withholding obligations related to the vesting of 992 restricted stock units (RSUs) on December 26, 2024.
• Following the transaction, Rahmer beneficially owns 389,663 shares of Relay Therapeutics, which includes 370,447 shares underlying RSUs.

Sentiment

Score: 5

Explanation: This is a routine transaction related to tax obligations and does not indicate a positive or negative sentiment towards the company's prospects.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives. This transaction is a routine part of executive compensation and does not necessarily indicate a change in the officer's confidence in the company.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen also see similar transactions by their executives regularly.
• These sales are typically viewed as a normal part of executive compensation and financial planning, rather than a reflection of the company's performance or future prospects.

Stakeholder Impact

• The sale of 400 shares is unlikely to have a significant impact on shareholders due to the small volume.
• Employees may see this as a normal part of executive compensation.

Key Dates